The progress of proteomic approaches in searching for cancer biomarkers

New Biotechnology

Volumn 30, Issue 3, 2013, Pages 319-326

  Kočevar, Nina ^a   Hudler, Petra ^a   Komel, Radovan ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL INTERACTIONS; BIOLOGICAL PROCESS; CANCER BIOMARKERS; CLINICAL ENVIRONMENTS; PATHOLOGICAL CONDITIONS; PATHOLOGICAL PROCESS; PROTEOMIC APPROACHES; PROTEOMIC TECHNOLOGIES;

DISEASES;

BIOMARKERS;

BIOLOGICAL MARKER; BRILLIANT BLUE; CALGRANULIN B; CARBOHYDRATE ANTIGEN; CARRIER PROTEIN; CLUSTERIN; FATTY ACID BINDING PROTEIN; FLOTILLIN 1; GALECTIN 2; GLYCAN; GOLD NANOPARTICLE; LIPID; MICRORNA; PROTEOME; QUANTUM DOT; RECOMBINANT ANTIBODY; SILVER NITRATE; SYNAPSIN II; TRIOSEPHOSPHATE ISOMERASE; TUMOR MARKER;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CELL COMMUNICATION; COLORECTAL CANCER; DIAGNOSTIC VALUE; DNA METHYLATION; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL GENOMICS; FUNCTIONAL PROTEOMICS; GENE ACTIVITY; GENE LOCATION; GENE MUTATION; GENETIC ALGORITHM; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LUNG CANCER; LYMPH NODE METASTASIS; MASS SPECTROMETRY; NANOTECHNOLOGY; PANCREAS CANCER; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN TARGETING; REPRODUCIBILITY; RNA SPLICING; SENSITIVITY AND SPECIFICITY; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SOMATIC MUTATION; STOMACH CANCER; TREATMENT FAILURE; TUMOR BLOOD FLOW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878110040     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.11.011     Document Type: Article

References (106)

1. Patterson M., Dhand R. Functional genomics. Nature 2000, 405:819.
2. Kilpinen H., Dermitzakis E.T. Genetic and epigenetic contribution to complex traits. Human Molecular Genetics 2012, 21:R24-R28.
3. Chin L., Gray J.W. Translating insights from the cancer genome into clinical practice. Nature 2008, 452:553-563.
4. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer 2005, 5:845-856.
5. Whiteaker J.R., Lin C., Kennedy J., Hou L., Trute M., Sokal I., et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nature Biotechnology 2011, 29:625-634.
6. Hanash S. Progress in mining the human proteome for disease applications. OMICS 2011, 15:133-139.
7. Ling M.M., Ricks C., Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Review of Molecular Diagnostics 2007, 7:87-98.
8. Kumar S., Mohan A., Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 2006, 11:385-405.
9. Omenn G.S. Strategies for plasma proteomic profiling of cancers. Proteomics 2006, 6:5662-5673.
10. Basu A., Rojas H., Banerjee H., Cabrera I.B., Perez K.Y., De Leon M., et al. Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. PLoS One 2012, 7:e30132.
11. Chen G., Gharib T.G., Huang C.C., Taylor J.M., Misek D.E., Kardia S.L., et al. Discordant protein and mRNA expression in lung adenocarcinomas. Molecular & Cellular Proteomics 2002, 1:304-313.
12. Kalinichenko S.V., Kopantzev E.P., Korobko E.V., Palgova I.V., Zavalishina L.E., Bateva M.V., et al. Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors. Lung Cancer 2008, 62:173-180.
13. Lichtinghagen R., Musholt P.B., Lein M., Romer A., Rudolph B., Kristiansen G., et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology 2002, 42:398-406.
14. Orntoft T.F., Thykjaer T., Waldman F.M., Wolf H., Celis J.E. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Molecular & Cellular Proteomics 2002, 1:37-45.
15. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer 2007, 6:25.
16. Vidal M., Chan D.W., Gerstein M., Mann M., Omenn G.S., Tagle D., et al. The human proteome-a scientific opportunity for transforming diagnostics, therapeutics, and healthcare. Clinical Proteomics 2012, 9:6.
17. Cho W.C., Cheng C.H. Oncoproteomics: current trends and future perspectives. Expert Review of Proteomics 2007, 4:401-410.
18. Dasilva N., Diez P., Matarraz S., Gonzalez-Gonzalez M., Paradinas S., Orfao A., et al. Biomarker discovery by novel sensors based on nanoproteomics approaches. Sensors (Basel) 2012, 12:2284-2308.
19. Frangogiannis N.G. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Translational Research 2012, 159:197-204.
20. Group B.D.W. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Pharmacology & Therapeutics 2001, 69:89-95.
21. Petricoin E., Wulfkuhle J., Espina V., Liotta L.A. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. Journal of Proteome Research 2004, 3:209-217.
22. Izzotti A. Molecular medicine and the development of cancer chemopreventive agents. Annals of the New York Academy of Sciences 2012, 1259:26-32.
23. Fang Q., Kani K., Faca V.M., Zhang W., Zhang Q., Jain A., et al. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One 2011, 6:e23090.
24. Makridakis M., Vlahou A. Secretome proteomics for discovery of cancer biomarkers. Journal of Proteomics 2010, 73:2291-2305.
25. Majewski I.J., Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine 2011, 17:304-312.
26. Polanski M., Anderson N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2006, 1:1-48.
27. Zieglschmid V., Hollmann C., Bocher O. Detection of disseminated tumor cells in peripheral blood. Critical Reviews in Clinical Laboratory Sciences 2005, 42:155-196.
28. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 2007, 253:180-204.
29. Mischak H., Coon J.J., Novak J., Weissinger E.M., Schanstra J.P., Dominiczak A.F. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrometry Reviews 2009, 28:703-724.
30. Geho D., Cheng M.M., Killian K., Lowenthal M., Ross S., Frogale K., et al. Fractionation of serum components using nanoporous substrates. Bioconjugate Chemistry 2006, 17:654-661.
31. Gonzalez-Gonzalez M., Jara-Acevedo R., Matarraz S., Jara-Acevedo M., Paradinas S., Sayagues J.M., et al. Nanotechniques in proteomics: protein microarrays and novel detection platforms. European Journal of Pharmaceutical Sciences 2012, 45:499-506.
32. Faca V., Krasnoselsky A., Hanash S. Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 2007, 43:279. 281-283, 285.
33. Liotta L.A., Petricoin E.F. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. Journal of Clinical Investigation 2006, 116:26-30.
34. Faca V., Pitteri S.J., Newcomb L., Glukhova V., Phanstiel D., Krasnoselsky A., et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. Journal of Proteome Research 2007, 6:3558-3565.
35. Apweiler R., Aslanidis C., Deufel T., Gerstner A., Hansen J., Hochstrasser D., et al. Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytometry A 2009, 75:816-832.
36. Fang X., Zhang W.W. Affinity separation and enrichment methods in proteomic analysis. Journal of Proteomics 2008, 71:284-303.
37. Luchini A., Fredolini C., Espina B.H., Meani F., Reeder A., Rucker S., et al. Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Current Molecular Medicine 2010, 10:133-141.
38. Polaskova V., Kapur A., Khan A., Molloy M.P., Baker M.S. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 2010, 31:471-482.
39. Qu X., Komatsu T. Molecular capture in protein nanotubes. ACS Nano 2010, 4:563-573.
40. Warder S.E., Tucker L.A., Strelitzer T.J., McKeegan E.M., Meuth J.L., Jung P.M., et al. Reducing agent-mediated precipitation of high-abundance plasma proteins. Analytical Biochemistry 2009, 387:184-193.
41. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
42. Lu M., Faull K.F., Whitelegge J.P., He J., Shen D., Saxton R.E., et al. Proteomics and mass spectrometry for cancer biomarker discovery. Biomark Insights 2007, 2:347-360.
43. Sabel M.S., Liu Y., Lubman D.M. Proteomics in melanoma biomarker discovery: great potential, many obstacles. International Journal of Proteomics 2011, 2011:181890.
44. O'Farrell P.H. High resolution two-dimensional electrophoresis of proteins. Journal of Biological Chemistry 1975, 250:4007-4021.
45. Rabilloud T., Chevallet M., Luche S., Lelong C. Two-dimensional gel electrophoresis in proteomics: past, present and future. Journal of Proteomics 2010, 73:2064-2077.
46. Miller I., Crawford J., Gianazza E. Protein stains for proteomic applications: which, when, why. Proteomics 2006, 6:5385-5408.
47. Kocevar N., Odreman F., Vindigni A., Grazio S.F., Komel R. Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers. World Journal of Gastroenterology 2012, 18:1216-1228.
48. Qian X., Li C., Pang B., Xue M., Wang J., Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One 2012, 7:e37225.
49. Hodgkinson V.C., ELFadl D., Agarwal V., Garimella V., Russell C., Long E.D., et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics 2012, 75:1276-1283.
50. Minden J.S. DIGE: past and future. Methods in Molecular Biology 2012, 854:3-8.
51. Liu W., Liu B., Cai Q., Li J., Chen X., Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clinica Chimica Acta 2012, 413:1098-1106.
52. Banerjee H.N., Mahaffey K., Riddick E., Banerjee A., Bhowmik N., Patra M. Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique. Molecular and Cellular Biochemistry 2012, 367:59-63.
53. Muto T., Taniguchi H., Kushima R., Tsuda H., Yonemori H., Chen C., et al. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. Journal of Proteomics 2011, 74:858-873.
54. Linge A., Kennedy S., O'Flynn D., Beatty S., Moriarty P., Henry M., et al. Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did not. Investigative Ophthalmology & Visual Science 2012, 53:4634-4643.
55. Olsson I., Larsson K., Palmgren R., Bjellqvist B. Organic disulfides as a means to generate streak-free two-dimensional maps with narrow range basic immobilized pH gradient strips as first dimension. Proteomics 2002, 2:1630-1632.
56. Hoving S., Gerrits B., Voshol H., Muller D., Roberts R.C., van Oostrum J. Preparative two-dimensional gel electrophoresis at alkaline pH using narrow range immobilized pH gradients. Proteomics 2002, 2:127-134.
57. Luche S., Diemer H., Tastet C., Chevallet M., Van Dorsselaer A., Leize-Wagner E., et al. About thiol derivatization and resolution of basic proteins in two-dimensional electrophoresis. Proteomics 2004, 4:551-561.
58. Bai F., Liu S., Witzmann F.A. A de-streaking method for two-dimensional electrophoresis using the reducing agent tris(2-carboxyethyl)-phosphine hydrochloride and alkylating agent vinylpyridine. Proteomics 2005, 5:2043-2047.
59. Gorg A., Obermaier C., Boguth G., Csordas A., Diaz J.J., Madjar J.J. Very alkaline immobilized pH gradients for two-dimensional electrophoresis of ribosomal and nuclear proteins. Electrophoresis 1997, 18:328-337.
60. Lane C.S. Mass spectrometry-based proteomics in the life sciences. Cellular and Molecular Life Sciences 2005, 62:848-869.
61. Himmelsbach M. 10 years of MS instrumental developments-impact on LC-MS/MS in clinical chemistry. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2012, 883-884:3-17.
62. Rotilio D., Della Corte A., D'Imperio M., Coletta W., Marcone S., Silvestri C., et al. Proteomics: bases for protein complexity understanding. Thrombosis Research 2012, 129:257-262.
63. Angel T.E., Aryal U.K., Hengel S.M., Baker E.S., Kelly R.T., Robinson E.W., et al. Mass spectrometry-based proteomics: existing capabilities and future directions. Chemical Society Reviews 2012, 41:3912-3928.
64. Principe S., Kim Y., Fontana S., Ignatchenko V., Nyalwidhe J.O., Lance R.S., et al. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. Journal of Proteome Research 2012, 11:2386-2396.
65. Sudhir P.R., Chen C.H., Pavana Kumari M., Wang M.J., Tsou C.C., Sung T.Y., et al. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells. Molecular & Cellular Proteomics 2012, 11:901-915.
66. Boja E.S., Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12:1093-1110.
67. Thelen J.J., Miernyk J.A. The proteomic future: where mass spectrometry should be taking us. Biochemical Journal 2012, 444:169-181.
68. Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Research 2012, 72:2428-2439.
69. Wang C.I., Chien K.Y., Wang C.L., Liu H.P., Cheng C.C., Chang Y.S., et al. Quantitative proteomics reveals regulation of KPNA2 and its potential novel cargo proteins in non-small cell lung cancer. Molecular & Cellular Proteomics 2012, 11:1105-1122.
70. Kang X., Sun L., Guo K., Shu H., Yao J., Qin X., et al. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. Journal of Cancer Research and Clinical Oncology 2010, 136:1151-1159.
71. Kang U.B., Ahn Y., Lee J.W., Kim Y.H., Kim J., Yu M.H., et al. Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. BMC Cancer 2010, 10:114.
72. Jung J.H., Kim H.J., Yeom J., Yoo C., Shin J., Yoo J., et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. Journal of Gastroenterology 2012, 47:37-48.
73. Masui O, White NM, Desouza LV, Krakovska O, Matta A, Metias S, et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Molecular & Cellular Proteomics, in press. doi:10.1074/mcp.M112.020701.
74. Zhang PF, Zeng GQ, Hu R, Li C, Yi H, Li MY, et al. Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. Journal of Proteomics, in press. doi:10.1016/j.jprot.2012.08.021.
75. Gautam P., Nair S.C., Gupta M.K., Sharma R., Polisetty R.V., Uppin M.S., et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 2012, 7:e46153.
76. Pham T.V., Piersma S.R., Oudgenoeg G., Jimenez C.R. Label-free mass spectrometry-based proteomics for biomarker discovery and validation. Expert Review of Molecular Diagnostics 2012, 12:343-359.
77. Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. European Journal of Cancer, in press. doi:10.1016/j.ejca.2012.07.031.
78. Whelan S.A., He J., Lu M., Souda P., Saxton R.E., Faull K.F., et al. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. Journal of Proteome Research 2012, 11:5034-5045.
79. Foss E.J., Radulovic D., Stirewalt D.L., Radich J., Sala-Torra O., Pogosova-Agadjanyan E.L., et al. Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets. Journal of Proteome Research 2012, 11:5005-5010.
80. Cazares L.H., Troyer D.A., Wang B., Drake R.R., Semmes O.J. MALDI tissue imaging: from biomarker discovery to clinical applications. Analytical and Bioanalytical Chemistry 2011, 401:17-27.
81. Seeley E.H., Caprioli R.M. 3D imaging by mass spectrometry: a new frontier. Analytical Chemistry 2012, 84:2105-2110.
82. Morgan TM, Seeley EH, Fadare O, Caprioli RM, Clark PE. Imaging the clear cell renal cell carcinoma proteome. Journal of Urology, in press. doi:10.1016/j.juro.2012.09.074.
83. Kang S., Maeng H., Kim B.G., Qing G.M., Choi Y.P., Kim H.Y., et al. In situ identification and localization of IGHA2 in the breast tumor microenvironment by mass spectrometry. Journal of Proteome Research 2012, 11:4567-4574.
84. Lazova R., Seeley E.H., Keenan M., Gueorguieva R., Caprioli R.M. Imaging mass spectrometry-a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. American Journal of Dermatopathology 2012, 34:82-90.
85. Berrade L., Garcia A.E., Camarero J.A. Protein microarrays: novel developments and applications. Pharmaceutical Research 2011, 28:1480-1499.
86. Chandra H., Reddy P.J., Srivastava S. Protein microarrays and novel detection platforms. Expert Review of Proteomics 2011, 8:61-79.
87. Gao L., Uttamchandani M., Yao S.Q. Comparative proteomic profiling of mammalian cell lysates using phosphopeptide microarrays. Chemical Communications (Cambridge) 2012, 48:2240-2242.
88. Wu C.S., Yen C.J., Chou R.H., Li S.T., Huang W.C., Ren C.T., et al. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. PLoS One 2012, 7:e39466.
89. Wingren C., Sandstrom A., Segersvard R., Carlsson A., Andersson R., Lohr M., et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Research 2012, 72:2481-2490.
90. Abajo A., Bitarte N., Zarate R., Boni V., Lopez I., Gonzalez-Huarriz M., et al. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World Journal of Gastroenterology 2012, 18:637-645.
91. O'Rourke D.J., DiJohnson D.A., Caiazzo R.J., Nelson J.C., Ure D., O'Leary M.P., et al. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clinica Chimica Acta 2012, 413:561-567.
92. He M. In vitro protein expression: an emerging alternative to cell-based approaches. New Biotechnology 2011, 28:209-210.
93. Nand A., Gautam A., Perez J.B., Merino A., Zhu J. Emerging technology of in situ cell free expression protein microarrays. Protein & Cell 2012, 3:84-88.
94. Qian J.Y., Mou S.H., Liu C.B. SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer. Asian Pacific Journal of Cancer Prevention 2012, 13:1911-1915.
95. Reddy P.J., Sadhu S., Ray S., Srivastava S. Cancer biomarker detection by surface plasmon resonance biosensors. Clinics in Laboratory Medicine 2012, 32:47-72.
96. Boschetti E., Chung M.C., Righetti P.G. The quest for biomarkers: are we on the right technical track. Proteomics - Clinical Applications 2012, 6:22-41.
97. Hudler P., Gorsic M., Komel R. Proteomic strategies and challenges in tumor metastasis research. Clinical & Experimental Metastasis 2010, 27:441-451.
98. Muyldermans S., Baral T.N., Retamozzo V.C., De Baetselier P., De Genst E., Kinne J., et al. Camelid immunoglobulins and nanobody technology. Veterinary Immunology and Immunopathology 2009, 128:178-183.
99. Rahbarizadeh F., Ahmadvand D., Sharifzadeh Z. Nanobody: an old concept and new vehicle for immunotargeting. Immunological Investigations 2011, 40:299-338.
100. Wesolowski J., Alzogaray V., Reyelt J., Unger M., Juarez K., Urrutia M., et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology 2009, 198:157-174.
101. Huang L., Muyldermans S., Saerens D. Nanobodies(R): proficient tools in diagnostics. Expert Review of Molecular Diagnostics 2010, 10:777-785.
102. de Marco A. Biotechnological applications of recombinant single-domain antibody fragments. Microbial Cell Factories 2011, 10:44.
103. Stoevesandt O., Taussig M.J. European and international collaboration in affinity proteomics. New Biotechnology 2012, 29:511-514.
104. Kastelic D., Frkovic-Grazio S., Baty D., Truan G., Komel R., Pompon D. A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. Journal of Immunological Methods 2009, 350:54-62.
105. Cox H, Webster A. Translating biomedical science into clinical practice: molecular diagnostics and the determination of malignancy. Health (London), in press. doi:10.1177/1363459312460701.
106. Ziegler A., Koch A., Krockenberger K., Grosshennig A. Personalized medicine using DNA biomarkers: a review. Human Genetics 2012, 131:1627-1638.